Giovanna Lattanzi Selected Research

Lamin Type A (Lamin A)

4/2022	Lamin A and the LINC complex act as potential tumor suppressors in Ewing Sarcoma.
1/2020	Long term breeding of the Lmna G609G progeric mouse: Characterization of homozygous and heterozygous models.
1/2020	PCAF Involvement in Lamin A/C-HDAC2 Interplay during the Early Phase of Muscle Differentiation.
1/2020	Lamin A involvement in ageing processes.
1/2020	Lamin A and Prelamin A Counteract Migration of Osteosarcoma Cells.
11/2019	Inhibition of DNA damage response at telomeres improves the detrimental phenotypes of Hutchinson-Gilford Progeria Syndrome.
1/2019	Statins and Histone Deacetylase Inhibitors Affect Lamin A/C - Histone Deacetylase 2 Interaction in Human Cells.
1/2019	Altered adipocyte differentiation and unbalanced autophagy in type 2 Familial Partial Lipodystrophy: an in vitro and in vivo study of adipose tissue browning.
1/2019	Ankrd2 in Mechanotransduction and Oxidative Stress Response in Skeletal Muscle: New Cues for the Pathogenesis of Muscular Laminopathies.
10/2018	Altered modulation of lamin A/C-HDAC2 interaction and p21 expression during oxidative stress response in HGPS.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Giovanna Lattanzi Research Topics

Disease

27	Laminopathies 02/2022 - 01/2005
12	Progeria (Hutchinson Gilford Syndrome) 01/2020 - 09/2009
12	Emery-Dreifuss Muscular Dystrophy (Scapuloperoneal Muscular Dystrophy) 01/2020 - 04/2003
8	Lipodystrophy 01/2022 - 06/2005
6	Neoplasms (Cancer) 04/2022 - 05/2015
6	Familial Partial Lipodystrophy (Dunnigan Syndrome) 10/2012 - 11/2003
5	Osteosarcoma (Osteogenic Sarcoma) 01/2021 - 03/2002
4	Genomic Instability 12/2021 - 11/2019
4	Cardiomyopathies (Cardiomyopathy) 04/2021 - 06/2012
4	Inborn Genetic Diseases (Disease, Hereditary) 04/2018 - 01/2005
3	Ewing Sarcoma (Sarcoma, Ewing) 04/2022 - 07/2004
3	Limb-Girdle Muscular Dystrophies (Limb-Girdle Muscular Dystrophy) 01/2020 - 12/2003
3	Muscular Dystrophies (Muscular Dystrophy) 10/2018 - 04/2011
3	Werner Syndrome (Werner's Syndrome) 07/2010 - 06/2005
2	Disease Progression 01/2019 - 06/2013
2	Autosomal Emery-Dreifuss Muscular Dystrophy 01/2019 - 01/2017
2	Bone Resorption 10/2015 - 09/2008
2	Rare Diseases (Rare Disease) 07/2011 - 09/2009
2	Osteolysis 07/2011 - 09/2008
1	Cardiac Sudden Death (Sudden Cardiac Arrest) 03/2022
1	Brain Diseases (Brain Disorder) 02/2022
1	Hypertrophy 01/2022
1	Carcinogenesis 01/2021
1	Kyphosis 01/2021
1	Inflammation (Inflammations) 01/2020
1	Atrial Fibrillation 11/2019
1	Bradycardia 01/2018
1	Melanoma (Melanoma, Malignant) 01/2018
1	Stroke (Strokes) 01/2018
1	Heart Failure 01/2018
1	Heart Diseases (Heart Disease) 01/2018
1	Ventricular Tachycardia 01/2018
1	Atherosclerosis 10/2015
1	Rhabdomyosarcoma 05/2015
1	Sarcoma (Soft Tissue Sarcoma) 05/2015
1	DNA Repair-Deficiency Disorders (Chromosome Instability Syndromes) 06/2013
1	Osteoporosis 09/2008
1	Cytomegalovirus Infections (Inclusion Disease) 03/2008
1	Infections 03/2008
1	Insulin Resistance 01/2007
1	Scleroatonic muscular dystrophy 01/2006

Drug/Important Bio-Agent (IBA)

28	Lamin Type A (Lamin A)IBA 04/2022 - 04/2003
16	prelamin AIBA 01/2020 - 06/2005
11	LaminsIBA 02/2022 - 11/2003
11	Proteins (Proteins, Gene)FDA Link 01/2022 - 12/2003
5	HeterochromatinIBA 01/2020 - 01/2007
4	emerinIBA 01/2020 - 04/2003
4	ChromatinIBA 03/2016 - 10/2005
3	Lamin Type B (Lamin B)IBA 02/2022 - 03/2008
2	Biological ProductsIBA 02/2022 - 07/2011
2	MicroRNAs (MicroRNA)IBA 01/2022 - 01/2020
2	DNA (Deoxyribonucleic Acid)IBA 12/2021 - 10/2011
2	DNA Transposable Elements (Element, IS)IBA 01/2020 - 01/2020
2	Transforming Growth Factor beta (TGF-beta)IBA 01/2020 - 04/2018
2	Biomarkers (Surrogate Marker)IBA 01/2020 - 01/2018
2	Carrier Proteins (Binding Protein)IBA 01/2019 - 04/2011
2	MTOR InhibitorsIBA 01/2019 - 11/2016
2	Sirolimus (Rapamycin)FDA Link 11/2016 - 10/2015
2	PPAR gammaIBA 06/2005 - 03/2002
1	desmuslin (synemin)IBA 04/2021
1	tocilizumab (atlizumab)FDA Link 01/2021
1	Karyopherins (Importin)IBA 01/2020
1	Interleukin-17 (Interleukin 17)IBA 01/2020
1	TESIBA 01/2020
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2020
1	Interleukin-4 (Interleukin 4)IBA 01/2020
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2020
1	CytokinesIBA 01/2020
1	Interleukin-8 (Interleukin 8)IBA 01/2020
1	ChemokinesIBA 01/2020
1	AF 57IBA 11/2019
1	Proto-Oncogene Proteins c-akt (Protein Kinase B)IBA 02/2019
1	Protein Isoforms (Isoforms)IBA 01/2019
1	Large-Conductance Calcium-Activated Potassium Channels (Maxi-K Channels)IBA 11/2018
1	Decitabine FDA Link 01/2018
1	AntigensIBA 01/2018
1	RNA (Ribonucleic Acid)IBA 01/2018
1	Therapeutic UsesIBA 11/2016
1	Small Interfering RNA (siRNA)IBA 03/2016
1	Histones (Histone)IBA 10/2015
1	Tretinoin (Retinoic Acid)FDA LinkGeneric 10/2015
1	MC1742IBA 05/2015
1	TubulinIBA 05/2015
1	MC2625IBA 05/2015
1	Histone Deacetylase InhibitorsIBA 05/2015
1	Cysteine (L-Cysteine)FDA Link 10/2011
1	1,2- di- (4- sulfamidophenyl)- 4- butylpyrazolidine- 3,5- dione (DSB)IBA 10/2011
1	lamina-associated polypeptide 2IBA 04/2011
1	Nuclear Matrix-Associated ProteinsIBA 04/2011
1	Peptides (Polypeptides)IBA 04/2011
1	Protein PrecursorsIBA 07/2010
1	Nuclear Localization Signals (Nuclear Localization Signal)IBA 07/2008
1	Viral ProteinsIBA 03/2008
1	Caveolin 1IBA 04/2006
1	CSK Tyrosine-Protein KinaseIBA 04/2006
1	CollagenIBA 01/2006
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 06/2005

Therapy/Procedure

3	Heart Transplantation (Grafting, Heart) 03/2022 - 10/2013
3	Therapeutics 01/2019 - 02/2008
1	Cardiac Resynchronization Therapy 01/2018